• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MUC16 Gene Record

  • Summary
  • Interactions
  • Claims
  • MUC16 94025 Druggable Genome

    Alternate Names:

    94025
    MUCIN 16, CELL SURFACE ASSOCIATED
    MUC16
    CA125
    606154
    15582
    ENSG00000181143
    OTTHUMG00000169191
    CA-125
    Mucin-16
    Ovarian cancer-related tumor marker CA125
    Ovarian carcinoma antigen CA125
    MUC-16
    Q8WXI7
    PA31314
    T05938

    Gene Info:

    Target Class Miscellaneous
    Target Subclass StructuralAndAdhesion
    Target Subclass Mucin_16
    Gene Biotype PROTEIN_CODING
    (4 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME

    Publications:

    Berek, 2004, Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab., Expert Opin Biol Ther
    2006, Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13., Drugs R D
    Felder M et al., 2014, MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress., Mol Cancer
    Marth et al., 1997, Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells., Cancer Res.
    Massacesi et al., Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer., Int. J. Biol. Markers
    Akashi et al., Dermatomyositis associated with membranous nephropathy in a 43-year-old female., Am. J. Nephrol.
    Coleman et al., 2007, Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients., Oncologist
    Hofstra et al., Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer., Anticancer Res.
    Fanning et al., 1991, Serial CA 125 levels during chemotherapy for metastatic or recurrent endometrial cancer., Obstet Gynecol
  • OREGOVOMAB   MUC16

    Interaction Score: 46.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Mechanism of Interaction Mucin-16 other
    Direct Interaction yes
    Trial Name oregovamab,OvaRex

    PMIDs:
    15268682 17073521 24886523


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • ABAGOVOMAB   MUC16

    Interaction Score: 23.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Mucin-16 other
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • SOFITUZUMAB VEDOTIN   MUC16

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TOPOTECAN   MUC16

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17227902


    Sources:
    NCI

  • ETOPOSIDE   MUC16

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1988893


    Sources:
    NCI

  • DOCETAXEL   MUC16

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9288793 14756546


    Sources:
    NCI

  • TAMOXIFEN   MUC16

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10629663


    Sources:
    NCI

  • CYCLOSPORINE   MUC16

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12169874


    Sources:
    NCI

  • Ensembl: ENSG00000181143

    • Version: 101_38

    Alternate Names:
    MUC16 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: Q8WXI7

    • Version: January-2014

    Alternate Names:
    MUC16 Gene Symbol

    Gene Info:
    Target Class Miscellaneous
    Target Subclass StructuralAndAdhesion
    Target Subclass Mucin_16

    Publications:

  • TTD: Ovarian carcinoma antigen CA125

    • Version: 2020.06.01

    Alternate Names:
    MUC16 TTD Gene Abbreviation
    T05938 TTD Target ID

    Gene Info:

    Publications:
    Felder M et al., 2014, MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress., Mol Cancer

  • NCI: MUC16

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Coleman et al., 2007, Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients., Oncologist
    Hofstra et al., Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer., Anticancer Res.
    Brooks et al., 1991, Effect of differentiation agents on expression of CA 125, alkaline phosphatase, and cytokeratins in human ovarian adenocarcinoma cells (OVCA 433)., Gynecol. Oncol.

  • HingoraniCasas: ENSG00000181143

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000181143 Gene Symbol
    MUC16 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: CA125

    • Version: chembl_23

    Alternate Names:
    CA125 GENE_SYMBOL
    MUC16 GENE_SYMBOL
    Mucin-16 UNIPROT

    Gene Info:

    Publications:

  • PharmGKB: MUC16

    • Version: 18-August-2020

    Alternate Names:
    PA31314 PharmGKB ID

    Gene Info:

    Publications:

  • ClearityFoundationClinicalTrial: MUC16

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21